Skip to main content

Table 2 Univariate Cox analyses predicting PFS and OS of corticosteroid switch

From: Corticosteroid switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone

 

N

PFS, months

OS, months

Median (95%CI)

HR (95%CI)

p value

Median (95%CI)

HR (95%CI)

p value

Age at corticosteroid switch, years

1.17 (0.70–1.98)

0.563

  ≥ 70

81

5.5 (4.4–6.6)

0.75 (0.51–1.10)

0.139

18.1 (16.7–19.5)

  < 70

49

3.2 (0.7–5.7)

  

23.5 (13.5–33.5)

ISUP grading at diagnosis

0.89 (0.51–1.55)

0.670

  > 4

75

4.8 (3.5–6.1)

1.01 (0.67–1.53)

0.946

20.1 (14.3–25.9)

  ≤ 4

43

5.5 (2.9–8.1)

  

17.3 (13.4–21.2)

ECOG at corticosteroid switch

0.58 (0.34–0.97)

0.037

 0

76

5.6 (4.2–7.0)

0.75 (0.51–1.10)

0.140

23.5 (17.3–29.7)

  ≥ 1

54

3.7 (2.2–5.2)

  

17.4 (13.8–21.0)

PSA at diagnosis, ng/mL

1.01 (0.58–176)

0.978

  ≥ 100

76

4.8 (3.7–5.9)

1.09 (0.71–1.65)

0.703

19.0 (14.2–23.8)

  < 100

41

5.9 (5.0–6.8)

  

18.1 (14.2–22.0)

PSA at corticosteroid switch, ng/mL

0.37 (0.21–0.54)

< 0.001

  ≤ 20

64

6.9 (5.8–8.0)

0.60 (0.41–0.87)

0.007

25.9 (21.7–30.1)

  >  20

66

3.7 (2.8–4.6)

  

15.6 (13.3–17.9)

mCRPC-free survival, months

0.51 (0.30–0.87)

0.014

  ≥ 18

53

6.9 (5.2–8.6)

0.58 (0.40–0.85)

0.005

23.6 (17.7–29.5)

  <  18

77

3.2 (2.0–4.4)

  

17.1 (15.1–19.1)

Time to progression on A + P, months

0.98 (0.58–1.65)

0.930

  ≥ 8

50

6.2 (4.5–7.9)

0.75 (0.51–1.10)

0.144

17.5 (15.3–19.7)

  < 8

80

4.2 (2.6–5.8)

  

19.0 (14.9–23.1)

PSA response on A + P

1.46 (0.86–2.46)

0.161

 Decline ≥50%

72

4.9 (3.8–6.0)

1.11 (0.75–1.62)

0.608

17.4 (16.2–18.7)

 Decline < 50%

58

5.4 (3.6–7.2)

  

28.3 (14.9–41.7)

  1. A: abiraterone acetate; CI: confidence interval; ECOG: Eastern Cooperative Oncology Group; HR: hazard ratio; ISUP: The International Society of Urological Pathology; mCRPC: metastatic castration-resistant prostate cancer; OS: overall survival; P: prednisone; PFS: progression-free survival; PSA: prostate-specific antigen